Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D'Sa S, Rabin N, Johnston R, Schey S, Yong K.
Moore S, et al. Among authors: schey s.
Eur J Haematol. 2013 May;90(5):420-5. doi: 10.1111/ejh.12070. Epub 2013 Mar 14.
Eur J Haematol. 2013.
PMID: 23294279